AION Labs, In Continued Partnership with BioMed X, Launches First 2023 Global Call for Applications: Developing Molecular Glues

AION Labs and German independent research institute BioMed X, announced the launch of its first 2023 global call for applications to identify technological and biomedical scientists and inventors to form a new startup at AION Labs’ headquarters in Rehovot, Israel.

Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS) seeks global research talent for new startup focused on: “AI Powered Discovery to Enable Molecular Glue Therapies.”

REHOVOT, Israel and HEIDELBERG, Germany, March 21, 2023 /PRNewswire/ -- AION Labs, a first-of-its-kind innovation lab spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, and German independent research institute BioMed X, announced today the launch of its first 2023 global call for applications to identify technological and biomedical scientists and inventors to form a new startup at AION Labs’ headquarters in Rehovot, Israel.

AION Labs Logo

AION Labs’ fifth startup will focus on the development of an AI platform that identifies naturally occurring protein of interest-E3 interacting pairs that work together in specific parts of the body under specific conditions. It is also looking to model the 3D structure of the interacting complex to enable small molecule design.

“Building on the successful launch and selection of four great startup founders for AION Labs in 2022, we are eager to tackle yet another pharmaceutical R&D challenge,” said Dr. Yair Benita, CTO of AION Labs. “We’re anticipating another strong round of applications, and look forward to working together with the chosen startup to develop a cutting-edge computational solution that will open an avenue to targeting proteins that have so far been seen as undruggable.”

AION Labs is inviting startups, computational biologists, bioinformatics and proteomics scientists, and AI and machine learning professionals to propose the development of a next-generation computational platform to identify naturally occurring protein of interest-E3 ligase interacting pairs to develop molecular glues. Original ideas that go far beyond the current state-of-the-art are being encouraged.

As part of the online application procedure, interested candidates are requested to submit a competitive project proposal via the BioMed X Career Space at before May 7, 2023. Further details about this call for application can be found on the AION Labs website:

About AION Labs

AION Labs is a first-of-its-kind alliance of Astrazeneca, Merck, Pfizer, Teva, the Israel Biotech Fund and Amazon Web Services (AWS), powered by BioMed X with the support of the Israeli Government via the Israel Innovation Authority and Digital Israel Initiative, that have come together with one clear mission: to create and adopt groundbreaking new AI technologies that will transform the process of drug discovery and development in order to contribute to the health and well-being of all people world-wide.

AION Labs is a unique venture hub where brilliant innovators and scientist-founders convene from around the world to solve the biggest R&D challenges guided by years of accumulated know-how, data and experience in pharma. The lab leverages its partners’ wealth of knowledge and a new multidisciplinary mindset with the ingenuity, agility and innovative power of Israel’s start-up ecosystem, to develop strong companies with clear long-term strategies, that will pave the way to the future of healthcare. AION Labs cultivates innovation from within; its unique venture creation process bridges the gap between outstanding academic research in the field of AI and the biggest R&D needs in the discovery and development of new medicines for the benefit of patients.

For more information, visit

About BioMed X

BioMed X is an independent research institute located on the campus of the University of Heidelberg in Germany, with a world-wide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world’s brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds – academia and industry – and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.

For more information, visit

Media Contact:

Raoul Wootliff
FINN Partners for AION Labs
+972 54 692 1720

Logo -

Cision View original content: